Organized by AIChE’s Society for Biological Engineering (SBE), the 8th International Conference on Accelerating Biopharmaceutical Development will be held September 6-8, 2023 in The Royal Sonesta Boston, Cambridge, MA.
Hear from AccBio Conference keynote speaker Raymond Deshaies about the future of biopharmaceutical development.
This award is presented to individuals or teams exhibiting exceptional leadership in industries served by chemical engineers.
Hear from James about promising career paths in cell-free systems, and get a preview of his upcoming talk at the Cell Free Systems Conference.
A common water plant's immune system offers a wide range of possibilities to help society, from wastewater treatment to antibiotics.
Twist Bioscience CEO, cofounder, and director Emily Leproust discusses the company's work and the promising future of synthetic biology.
Suddenly, synthetic biology is being discussed a lot beyond the walls of academia and the pages of scientific journals. Today, it abounds in the mainstream press.
Understanding the bivalve genome and the mechanisms of how they fight disease could lead to new drugs, therapies, and novel biomaterials.
Hear Ryan's perspective on what advances he thinks chemical engineering has ahead of it.
A look at the future of chemical engineering from the perspective of pharmaceutical manufacturing.
A new experimental broad-spectrum antiviral drug could be used to combat the type of virus that causes the common cold and pneumonia, as well as more lethal viruses such as SARS and MERS.
Technique allows for the observation of how cells and molecules react in their natural environment, presenting possibilities for biomedical and pharmaceutical applications.
A new report released by the European Centre for Disease Prevention and control (ECDC) emphasizes that antimicrobial resistance remains one of the greatest public health threats today.
An international team of researchers has created new antiviral nanoparticles that show potential for outperforming current antiviral drugs.
New imagine of a key protein's signaling mechanism provides insights for better pharmaceuticals.
Researchers at the University of Nebraska-Lincoln have uncovered clues about how the Zika virus became much more dangerous in recent years.
Researchers have identified an inherited genetic variation that they believe helps identify those at the highest risk for potentially fatal influenza infections.
A new technique labels gene segments to help understand how the virus enters a cell and establishes co-infections.
In its first year, BioTM is already topping the charts, with top ratings for viewing, sharing, and discussion of articles.
The failure rate for new drugs and therapies under development exceeds 95%.
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have published findings that may represent a first step towards a drug treatment for Zika infections.
A compound found in a snail's venom yields pain-fighting effects in testing, presenting a possible opioid alternative.
Researchers at Indiana University Bloomington have discovered that a molecule related to some forms of cancer and neurodegenerative disorders is also present in developing Drosophila
As we approach ICBE 2017, which begins this weekend in San Diego, we look back at some of the exciting research that figured among 2016's highlights and look forward to the new developments to be unveiled at ICBE 2017.
Researchers at the University of Michigan have had a significant breakthrough in creating a customized therapeutic vaccine for treating colon and melanoma cancer tumors in mice.
This special issue focuses on smart and precision medications, presenting novel work aimed at a wide range of medical applications, from diabetes treatments, cancer therapy, tissue engineering, drug delivery, and more.
Researchers at the University of California, Riverside, recently published work that suggests that the usefulness of studying pro- and anti-apoptotic proteins in a search for cancer
The 2016 D.I.C.
By Dr. Jyotika Virmani
A startup in southern California is designing microbes that extend DNA beyond the natural A, T, G, and C components to include X and Y.
It sounds like something straight out of a science fiction movie: bacteria that feeds on human flesh.
The U.S. government announced this week that it is putting aside $55 million to create a public database with health information on about one million volunteers.
